Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1997 Feb;88(2):160–165. doi: 10.1111/j.1349-7006.1997.tb00361.x

Gene Mutation Analysis and Quantitation of DNA Topoisomerase I in Previously Untreated Non‐small Cell Lung Carcinomas

Hiroshi Takatani 1, Mikio Oka 1,✉, Minoru Fukuda 1, Fumihiko Narasaki 1, Reiji Nakano 1, Koki Ikeda 1, Kenji Terashi 1, Akitoshi Kinoshita 1, Hiroshi Soda 1, Tetsuro Kanda 1, Erasmus Schneider 2, Shigeru Kohno 1
PMCID: PMC5921358  PMID: 9119744

Abstract

To elucidate whether gene alterations of topoisomerase I (topo I) exist in untreated non‐small cell lung carcinomas (NSCLC), polymerase chain reaction‐single strand conformation polymorphism analysis was performed in forty‐four NSCLC tissue samples. Gene alterations of topo I were sought in three regions, near codons 361 and 363, 533, and 722 and 729, where point mutations have been found in resistant tumor cell lines selected by chronic camptothecin exposure. In addition, nuclear topo I contents were determined by immunoblotting. No mobility shifts were observed compared to the pattern observed in a normal control at any of the three regions in any sample, whereas topo I levels showed an approximately 12‐fold variation. The variation is remarkably large compared to those seen in previous in vitro and in vivo studies. The results suggest that mutations of topo I may not contribute to intrinsic resistance of NSCLC to camptothecins, but low topo I levels may account, at least in part, for the resistance.

Keywords: Lung cancer, Topoisomerase I, Drug resistance, Camptothecin mutation Gene

Full Text

The Full Text of this article is available as a PDF (363.2 KB).

REFERENCES

  • 1. ) Liu , L. F.DNA topoisomerase poisons as antitumor drugs . Annu. Rev. Siochem. , 58 , 351 – 375 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Slichenmyer , W. J. , Rowinsky , E. K. , Donehower , R. C. and Kaufmann , S. H.The current status of camptothecin anologues as antitumor agents . J, Natl. Cancer Inst. , 85 , 271 – 291 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Guputa , M. , Fujimori , A. and Pommier , Y.Eukaryotic DNA topoisomerase I . Biochim. Biophys. Acta , 1262 , 1 – 14 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Qiovanella , B. C. , Steblin , J. S. , Wall , M. E. , Wani , M. C. , Nicholas , A. W. , Liu , L. F. , Silber , R. and Potmesil , M.DNA topoisomerase I‐targeting chemotherapy of human colon cancer in xenografts . Science , 246 , 1046 – 1048 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Takano , H. , Kohno , K. , Matsuo , K. , Matsuda , T. and Kuwano , M.DNA topoisomerase‐targeting antitumor agents and drug resistance . Anti-Cancer Drugs , 3 , 323 – 330 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Fukuoka , M. , Niitani , H. , Suzuki , A. , Motomiya , M. , Hasegawa , K. , Nishiwaki , Y. , Kuriyama , T. , Ariyoshi , Y. , Negoro , S. , Masuda , N. , Nakashima , S. and Taguchi , T.A phase II study of CPT‐11, a new derivative of camptothecin, for previously untreated non‐small cell lung cancer . J. Clin. Oncol. , 10 , 16 – 20 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Masuda , N. , Fukuoka , M. , Kusunoki , Y. , Matsui , K. , Takifuji , N. , Kudoh , S. , Negoro , S. , Nishioka , M. , Nakagawa , K. and Takada , M.CPT‐11: a new derivative of camptothecin for the treatment of refractory or relapsed small‐cell lung cancer . J. Clin. Oncol. 10 , 1225 – 1229 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Tsuda , H. , Takatsuki , K. , Ono , R. , Masaoka , T. , Okada , K. , Shirakawa , S. , Ohashi , Y. , Ota , K.and the CPT‐11 study group on hematological malignancy, Tokyo, Japan Treatment of adult T‐cell leukemia‐lymphoma with ir‐inotecan hydrochloride (CPT‐11) . Br. J. Cancer , 70 , 771 – 774 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. ) Fukuoka , M. and Masuda , N.Clinical studies of irinotecan alone and in combination with cisplatin . Cancer Chemother. Pharmacol , 34 , S105 – S111 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Wagener , D. J. T. , Verdonk , H. E. R. , Dirix , L. Y. , Catimel , G. , Siegenthaler , P. , Buitenhuis , M. , Mathieu‐Boue , A. and Verweij , J.Phase II trial of CPT‐11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study . Anal. Oncol , 6 , 129 – 132 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Conti , J. A. , Kemeny , N. E. , Saltz , L. B. , Huang , Y. , Tong , W. P. , Chou , T. , Sun , M. , Pulliam , S. and Gonzalez , C.Irinotecan is an active agent in untreated patients with metastatic colorectal cancer, J . Clin. Oncol. , 14 , 709 – 715 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Chen , A. Y. and Liu , A. F.Mechanisms of resistance to topoisomerase inhibitors . In “ Anticancer Drug Resistance, Advances in Molecular and Clinical Research ,” ed. Goldstein L. J. and Ozols R. F. pp. 263 – 281 ( 1995. ). Kluwer Academic Publishers; , Norwell . [Google Scholar]
  • 13. ) Rubin , E. , Pantazis , P. , Bharti , A. , Toppmeyer , D. , Giovanella , B. and Kufe , D.Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9‐nitrocamptothecin . J. Biol Chem. , 269 , 2433 – 439 ( 1994. ). [PubMed] [Google Scholar]
  • 14. ) Benedictti , P. , Fiorani , P. , Capuani , L. and Wang , J. C.Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cystine . Cancer Res. , 53 , 4343 – 4348 ( 1993. ). [PubMed] [Google Scholar]
  • 15. ) Tamura , H. , Kohchi , C. , Yamada , R. , Ikeda , T. and Koiwai , O.Molecular cloning of a cDNA of a camptothecine‐resistant human DNA topoisomerase I and identification of mutation sites . Nucleic Acids Res. , 19 , 69 – 75 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. ) Fujimori , A. , Harker , W. G. , Kohlhagen , G. , Hoki , Y. and Pommier , Y.Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin . Cancer Res. , 55 , 1339 – 1346 ( 1995. ). [PubMed] [Google Scholar]
  • 17. ) Kubota , N. , Ohmori , T. , Fujiwara , Y. , Terashima , Y. and Saijo , N.Detection of topoisomerase I gene point mutation in CPT‐11 resistant lung cancer cell line . Biochem. Biophys. Res. Commtm. , 188 , 571 – 577 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Chomczynski , P. and Sacchi , N.Single step method of RNA isolation by acid guanidinium thiocyanate‐phenol‐chloroform extraction . Anal. Biochem. , 162 , 156 – 159 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) D'Arpa , P. , Machlin , P. S. , Ratrie , III , H. , Rothfleld , N. F. , Cleveland , D. W. and Earnshaw , W. C.cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7‐kDa carboxy‐terminal fragment . Proc. Natl. Acad. Sci. USA , 85 , 2543 – 2547 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. ) Mohabeer , A. J. , Hiti , A. L , and Martin , W. J.Non‐radioactive single strand conformation polymorphism (SSCP) using the Pharmacia 'PhastSystem.' Nucleic Acids Res. , 19 , 3154 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. ) Langemeier , J. L. , Cook , R. F. , Issel , C. J. and Montelaro , R. C.Comparative sensitivity of alternative single‐strand conformation polymorphism (SSCP) methods . BioTechniques , 17 , 490 – 496 ( 1994. ). [PubMed] [Google Scholar]
  • 22. ) Bender , T. P.Identification of newly transcribed RNA . In “ Current Protocols in Molecular Biology, Vol. 1, Unit 4. 10. IF ,” ed. Ausubel M. , Brent R. , Kingston R. E. , Moore D. D. , Seidman J. G. , Smith J. A. and Struhl K. ( 1993. ). John Wiley & Sons, Inc. , New York . [DOI] [PubMed] [Google Scholar]
  • 23. ) Laemmli , U. K.Cleavage of structural proteins during the assembly of the head of bacteriophage T4 . Nature , 227 , 680 – 685 ( 1970. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Hasegawa , T. , Isobe , K. , Nakashima , I. and Shimokata , K.Higher expression of topoisomerase II in lung cancers than normal lung tissues: different expression pattern from topoisomerase I . Biochem. Biophys. Res, Commun. , 195 , 409 – 414 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Ohashi , N. , Fujiwara , Y. , Isobe , T. , Sumiyoshi , H. , Murakami , I. , Okusaki , K. , Niitani , K. , Egusa , Y. , Yamaoka , N. , Yamakido , M. , Katoh , O. , Kimura , A. and Satow , Y.Topoisomerase I gene alteration in tumor samples from lung cancer patients . Proc. Am. Assoc. Cancer Res. , 36 , 640 ( 1995. ). [Google Scholar]
  • 26. ) Kubo , A. , Yoshikawa , A. , Hirashima , T. , Masuda , N. , Takada , M. , Takahara , J. , Fukuoka , M. and Nakagawa , K.Point mutations of the topoisomerase Ha gene in patients with small cell lung cancer treated with etoposide . Cancer Res. , 56 , 1232 – 1236 ( 1996. ). [PubMed] [Google Scholar]
  • 27. ) Mcleod , H. L. , Douglas , F. , Dates , M. , Symonds , R. P. , Prakash , D. , van der Zee , A. G. J. , Kaye , S. B. , Brown , R. and Keith , W. N.Topoisomerase I and II activity in human breast, cervix, lung and colon cancer . Int. J. Cancer , 59 , 607 – 611 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Goldwasser , F. , Bae , I. , Valenti , M. , Torres , K. and Pommier , Y.Topoisomerase I‐related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen . Cancer Res. , 55 , 2116 – 2121 ( 1995. ). [PubMed] [Google Scholar]
  • 29. ) Sugimoto , Y. , Tsukahara , S. , Oh‐hara , T. , Isoe , T. and Tsuruo , T.Decreased expression of DNA topoisomerase I in camptothecin‐resistant tumor cell lines as determined by a monoclonal antibody . CancerRes. , 50 , 6925 – 6930 ( 1990. ). [PubMed] [Google Scholar]
  • 30. ) Takeda , S. , Shimazoe , T. , Sato , Y. K. , Sugimoto , Y. , Tsuruo , T. and Kono , A.Differential expression of DNA topoisomerase I gene between CPT‐11 acquired‐ and native‐resistant human pancreatic tumor cell lines: detected by RNA/PCR‐based quantitation assay . Biochem. Biophys. Res. Commun. , 184 , 618 – 625 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 31. ) Husain , I. , Mohler , J. L. , Seigler , H. F. and Besterman , J. M.Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstrationof tumor‐type specificity and implicationsfor cancer chemotherapy . Cancer Res. , 54 , 539 – 546 ( 1994. ). [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES